Understanding the cellular and humoral immunity to COVID-19 is necessary to assess the future course of the pandemic. The impact of SARS-CoV-2 on human health in individuals and populations depends on multiple factors such as the level of healthcare, diagnostics, therapeutics, social distancing measures such as lockdowns, face masks, working from home, and the availability and coverage of vaccines to control the disease. The estimated seroprevalence of SARS CoV-2 antibodies in Norway was 0.6% in the late summer of 2020 and increased to 3.2% in January 2021, after the second wave. The second wave started in the autumn of 2020 and the third wave in February 2021. The first wave of the pandemic in Norway peaked in March 2020. Since the initial outbreak of COVID-19 was reported in Wuhan in December 2019, over 304 million people have been infected worldwide, with over 5.4 million deaths reported by the World Health Organization (WHO) as of 11th January 2022. However, data requests for the minimal dataset, which includes only the main variables of the final analyses, can be made to the Research Department at The Telemark Hospital Trust, UlefossveSkien, Norway email: The authors received no specific funding for this work.Ĭompeting interests: The authors have declared that no competing interests exist. The potentially identifying patient information is age, birthdate, location and dates for PCR and antibody tests. Our data set is not fully anonymized and has a relative small sample size making identification of individuals possible. The project is approved by the Regional Committees for Medical and Health Research Ethics (ID 146469), and by the Data Protection Officers in the participating Hospitals. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.ĭata Availability: There are legal and ethical restrictions on sharing our dataset. Received: FebruAccepted: JPublished: August 10, 2022Ĭopyright: © 2022 Sarjomaa et al. PLoS ONE 17(8):Įditor: Mohammed Abdelfatah Mosa Alhoot, Management and Science University, MALAYSIA (2022) SARS-CoV-2 antibody persistence after five and twelve months: A cohort study from South-Eastern Norway. Citation: Sarjomaa M, Diep LM, Zhang C, Tveten Y, Reiso H, Thilesen C, et al.
0 Comments
Leave a Reply. |